BMY vs CAH
BMY: A diversified biopharmaceutical company leveraging immunotherapy, cell therapies, and small-molecule platforms to address cancer, autoimmune disease, and specialty care. CAH: Cardinal Health is a healthcare services and logistics company that distributes pharmaceuticals, medical supplies, and healthcare IT solutions to pharmacies, hospitals, and health systems globally.
Side-by-side fundamentals
| Metric | BMY | CAH | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $57.94 | $233.77 | |
| Market cap as of 2026-07-10 | $117.7B | $55.3B | |
| P/E as of 2026-07-10 | 19.69 | 35.56 | BMY lower |
| PEG as of 2026-07-10 | -4.29 | 2.07 | BMY lower |
| Net margin as of 2026-07-10 | +12.3% | +0.6% | BMY higher |
| Gross margin as of 2026-07-10 | +53.7% | +3.8% | BMY higher |
| Operating margin as of 2026-07-10 | +17.1% | +0.9% | BMY higher |
| ROE as of 2026-07-10 | +41.6% | +37.2% | BMY higher |
| ROA as of 2026-07-10 | +8.7% | +2.8% | BMY higher |
| Debt / equity as of 2026-07-10 | 2.22 | 5.65 | BMY lower |
| Revenue growth (YoY) as of 2026-07-10 | +1.8% | +12.9% | CAH higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +7.1% | CAH higher |
| Dividend yield as of 2026-07-10 | +4.4% | +0.9% | BMY higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.24 | 0.52 | |
| 1-year return as of 2026-07-09 close | +22.3% | +42.3% | CAH higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.